Saikat  Das

Dr. Saikat Das


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in Indian Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
SDSaikat Das
Saikat Das
LJLavanya Jagan
Lavanya Jagan
RIRajesh Isiah
Rajesh Isiah
BRB Rajesh
B Rajesh
SBSelvamani Backianathan
Selvamani Backianathan
JSJ Subhashini
J Subhashini
Context: Nanotechnology is an empowering technology that holds promise in cancer therapeutics by increasing the ratio of tumor control probability to normal tissue complication probability. It can increase the bioavailability of the drug at the target site, reduce the frequency of administration and reach otherwise lesser-accessible sites. The present study shows the feasibility of the cisplatin-loaded albumin nanoparticle as a sustained delivery system. Aims: Cisplatin is one of the most widely used chemotherapeutic agents for the treatment of malignant disorders. Conventional cisplatin formulation given as intravenous infusion has low bioavailability to the target organ in addition to significant side-effects, like ototoxicity and nephrotoxicity. The aim of this study was to develop a protein-based nanoparticulate system for sustained release of cisplatin. Materials and Methods: Nanoparticles were prepared by the coacervaton method of microcapsulation and chemical cross-linking with glutaraldehyde. Particle size was characterized by dynamic light scattering and transmission electron microscopy. Results and Conclusions: Using the coacervation method, nanoparticles of less than 70 nm diameter were produced. Drug encapsulation measured by ultraviolet spectroscopy varied from 30% to 80% for different ratios of cisplatin and protein. In vitro release kinetics shows that the nanoparticle-based formulation has biphasic release kinetics and is capable of sustained release compared with the free drug (80% release in 45 h). The study proves the feasibility of the albumin-based cisplatin nanoparticle formulation as a sustained release vehicle of cisplatin.

1 January 2013 in Indian Journal of Palliative Care
Verified
Journal Article
Open access
PDF file
SDSaikat Das
Saikat Das
STSolly Thomas
Solly Thomas
SPSuparna Kanti Pal
Suparna Kanti Pal
RIRajesh Isiah
Rajesh Isiah
SJSubhashini John
Subhashini John
Background: A novel, short duration, palliative radiotherapy schedule for inoperable head and neck cancer was evaluated in terms of palliation of cancer-related symptoms and acute toxicities. Materials and Methods: Thirty-six patients with inoperable head and neck cancer were included in the study (2010-2012). All patients received 40 Gy in 10 fractions (equivalent dose: 49.8 Gy in conventional fractionation) with 2 fractions per week. Treatment-related toxicity was assessed using Radiation Therapy Oncology Group criteria. Functional Assessment of Cancer Therapy (Head and Neck, FACT H and N) quality of life (QOL) tool was administered before starting and at the completion of radiotherapy. Mean value before and after treatment was compared (paired t-test, P = 0.05, two-tailed for significance). Results: Thirty-three patients (male: 29, female: 4, mean age: 57.8 ± 9.7 years) were included in the analysis (three patients discontinued treatment due to socioeconomic reasons). All patients had advanced inoperable head and neck cancers (27% IVA, 61% IVB, 9% IVC, TNM stage and 3% recurrent disease). Distressing pain at primary site (42%), dysphagia (18%), neck swelling (30%), and hoarseness (10%) were common presentations. Incidence of grade III mucositis and dermatitis and pain was 18%, 3%, and 24%, respectively. Planned radiotherapy without any interruptions was completed by 73% patients. QOL assessment showed improvement in social well-being (17.4 vs. 20.01, P = 0.03), but no significant change was observed in head and neck specific score (25.1 vs. 25.0, P = NS) after treatment. Reduction of pain was observed in 88% patients and 60% patients had improvement of performance status. Median overall survival of the cohort was 7 months. Conclusions: The study shows that this short duration palliative radiotherapy schedule is a clinically viable option for advanced inoperable head and neck cancer to achieve significant palliation of the main presenting symptoms like pain, dysphagia, and throat pain.

1 November 2015 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
SDSaikat Das
Saikat Das
ACAnuradha Chandramohan
Anuradha Chandramohan
JRJeba Karunya Rami Reddy
Jeba Karunya Rami Reddy
SMSramana Mukhopadhyay
Sramana Mukhopadhyay
RKRamani Manoj Kumar
Ramani Manoj Kumar
VJVisalakshi Jeyaseelan
Visalakshi Jeyaseelan

1 August 2015 in Gynecologic Oncology
Verified
Journal Article
Closed access
SDSaikat Das
Saikat Das
JSJ. Subhashini
J. Subhashini
JRJeba Karunya Rami Reddy
Jeba Karunya Rami Reddy
SKSuparna KantiPal
Suparna KantiPal
RIRajesh Isiah
Rajesh Isiah
RORegi Oommen
Regi Oommen

1 January 2015 in Journal of Clinical and Diagnostic Research
Verified
Journal Article
Open access
SDSaikat Das
Saikat Das
Purpose of the present study was to examine the response of cervical cancer cell line (HeLa cell line) to low dose radiation using clonogenic assay and mathematical modeling of the low dose response by Joiner's induced repair model. Survival of HeLa cells following exposure to single and fractionated low doses of γ (gamma)-ray, 6 MV, and 15 MV photon was measured by clonogenic assay. HeLa cell line demonstrated marked low dose response consisting of an area of HRS and IRR in the dose region of <1 Gy. The two gradients of the low dose region (αs and αr) were distinctly different with a transition dose (Dc) of 0.28-0.40 cGy. HeLa cell line demonstrates marked HRS and IRR with distinct transition dose. This may form the biological basis of the clinical study to investigate the chemo potentiating effect of low dose radiation in cervical cancer.

28 June 2011 in Journal of Gastrointestinal Cancer
Verified
Journal Article
Closed access
PDF file
SDSaikat Das
Saikat Das
JSJ. Subhashini
J. Subhashini
RIRajesh Isiah
Rajesh Isiah
SKSusy Kurian
Susy Kurian